Ibere Pharmaceuticals Overview
Get informed when a big investor buys or sells
+ Follow29.94
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
Ibere Pharmaceuticals posts a P/E ratio of 29.94. That is above the sector sector average of 22.75. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.
For its sector stocks, a P/E ratio near 22.75 is typical. Ibere Pharmaceuticals's 29.94 is higher that level. That is roughly 31.6% above the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.
Ibere Pharmaceuticals's P/E ratio of 29.94 comes from dividing a price-based measure by a related financial statistic. Changes can come from the stock price moving, the underlying fundamental shifting, or both. Track both the level and the trend — a rising multiple on falling fundamentals is a different story than a rising multiple on rising earnings.
Context for IBER's P/E ratio usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 22.75), and (3) consistency with growth and profitability. This page covers the first two; Ibere Pharmaceuticals's other metric pages and overview cover the third.
